| 18.07 0.71 (4.09%) | 11-06 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 22.19 | 1-year : | 25.92 |
| Resists | First : | 19 | Second : | 22.19 |
| Pivot price | 16.77 |
|||
| Supports | First : | 15.99 | Second : | 14.13 |
| MAs | MA(5) : | 17.86 |
MA(20) : | 16.37 |
| MA(100) : | 20.94 | MA(250) : | 19.33  |
|
| MACD | MACD : | 0.1 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 78.8 |
D(3) : | 85.6 |
| RSI | RSI(14): 57.1 |
|||
| 52-week | High : | 27.3 | Low : | 14 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ DYN ] has closed below upper band by 16.3%. Bollinger Bands are 13.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 18.35 - 18.42 | 18.42 - 18.49 |
| Low: | 17.2 - 17.29 | 17.29 - 17.37 |
| Close: | 17.92 - 18.06 | 18.06 - 18.19 |
Dyne Therapeutics, Inc. is a U.S.-based biotechnology firm focused on developing advanced treatments for genetically driven muscle disorders. Utilizing its proprietary FORCE platform, which is engineered to deliver disease-modifying therapeutics, the company is actively engaged in various programs. These initiatives target conditions such as myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral dystrophy, in addition to other rare skeletal, cardiac, and metabolic muscle diseases. The company was founded in 2017 and maintains its corporate headquarters in Waltham, Massachusetts.
Fri, 06 Nov 2026
symbol__ Stock Quote Price and Forecast - CNN
Mon, 02 Nov 2026
Dyne Therapeutics, Inc. (DYN) Seasonal returns chart - Yahoo Finance - Yahoo Finance Singapore
Wed, 28 Oct 2026
DYN: Dyne Therapeutics Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Tue, 06 Oct 2026
At $16 a share, director Brian S. Posner buys 2,500 Dyne Therapeutics (DYN) shares. - Stock Titan
Fri, 04 Sep 2026
Dyne Therapeutics (NASDAQ: DYN) officer plans $121,745 share sale - Stock Titan
Thu, 03 Sep 2026
Dyne Therapeutics to Present Preclinical Data for Multiple - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 187 (M) |
| Shares Float | 186 (M) |
| Held by Insiders | 0.2 (%) |
| Held by Institutions | 103.4 (%) |
| Shares Short | 25,980 (K) |
| Shares Short P.Month | 20,790 (K) |
| EPS | -3.3 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.23 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -39 % |
| Return on Equity (ttm) | -81.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.87 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -478 (M) |
| Levered Free Cash Flow | -317 (M) |
| PE Ratio | -5.48 |
| PEG Ratio | 0 |
| Price to Book value | 4.26 |
| Price to Sales | 0 |
| Price to Cash Flow | -7.07 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|